What Is the Difference Between a Bladder Sling and Mesh?

A bladder sling is a specific surgical procedure, and mesh is the material that sling is usually made from. In everyday conversation and even in some medical settings, the two words get used interchangeably, which creates real confusion. That confusion deepened after the U.S. Food and Drug Administration banned one particular use of surgical mesh in 2019, and news coverage frequently failed to clarify which procedures were affected and which were not. The distinction matters because midurethral slings for stress urinary incontinence remain a well-supported treatment, while transvaginal mesh for pelvic organ prolapse is the product class that drew regulatory action.

Why the Two Terms Get Confused

A “sling” refers to the operation itself: a strip of material is placed under the urethra, like a hammock, to support it and prevent leakage during coughing, sneezing, or physical activity. In most modern sling procedures, the strip is made of synthetic polypropylene mesh. So a bladder sling contains mesh, and the mesh is shaped into a sling. The words describe two different aspects of the same device.

The confusion gets worse because the same mesh material, polypropylene, has also been used in a completely different operation: transvaginal mesh kits for pelvic organ prolapse, where larger sheets of mesh are implanted through the vagina to hold up organs that have dropped from their normal position. That procedure is what the FDA targeted. The sling procedure for incontinence was not banned and continues to be widely performed.

A study examining news coverage of the 2019 FDA ban found that 70% of reports failed to distinguish between the clinical uses of mesh affected by the ban and those that were not.¹ This blurred reporting left many patients under the impression that all mesh-based surgeries had been deemed unsafe.

What a Midurethral Sling Does

Stress urinary incontinence happens when the muscles and connective tissue supporting the urethra weaken, often after childbirth or with aging. A midurethral sling provides a backstop. The narrow strip of mesh sits beneath the middle portion of the urethra, and when you cough or strain, the urethra presses against it and stays closed. Research using ultrasound imaging has shown that the urethra actually has two closure mechanisms: one at the distal end and one at the bladder neck.² The sling supports the midurethral zone to restore that closure when internal pressure spikes.

The sling itself is typically a narrow strip, roughly one centimeter wide, made from a lightweight polypropylene mesh. It is not stitched tightly in place; instead, it sits loosely enough that the body’s own tissue grows into the mesh pores over the following weeks, anchoring it naturally. This is very different from the larger mesh sheets used in prolapse repair, which cover more tissue surface area and have been linked to higher rates of complications.

How Mesh for Prolapse Differs

Pelvic organ prolapse is a separate condition where the bladder, uterus, or rectum drops into the vaginal canal because the supporting tissues have weakened. Surgeons have tried using mesh in this setting to get a stronger, longer-lasting repair than stitching the patient’s own tissue back together. Randomized trials found that mesh did produce better anatomical results, meaning the organs stayed in a more normal position on examination. But functional outcomes, the symptoms patients actually cared about, were similar, and meshes were associated with more complications, especially when placed transvaginally.³

A five-year follow-up trial comparing mesh to native tissue repair for prolapse confirmed the pattern: the mesh group had better cure rates in the front vaginal wall and better quality-of-life scores, but significantly more complications. The native tissue group had more recurrence of prolapse but also needed fewer interventions for complications. Reoperation rates overall were similar between the two groups, though the reasons for reoperation differed.⁴ That tradeoff, better anatomy but more complications, is what ultimately led regulators to pull transvaginal mesh kits for prolapse off the market in several countries.

The chronic pain picture starkly illustrates the difference between the two uses of mesh. A systematic review found that chronic pain occurred in about 6.7% of patients who received mesh for prolapse, compared with just 0.6% of those who received mesh slings for stress incontinence.⁵ The difference is more than tenfold, and it is one of the clearest reasons the regulatory story diverged for these two uses of what is physically the same material.

Retropubic Versus Transobturator Slings

When you hear surgeons talk about specific sling types, they are usually distinguishing the route the mesh tape takes through your body. The two dominant approaches are the retropubic sling (TVT, for tension-free vaginal tape) and the transobturator sling (TOT or TVT-O). Both use a similar strip of polypropylene mesh to support the urethra, but they pass through different anatomical spaces to anchor each end of the tape.

The retropubic approach threads the tape behind the pubic bone, passing near the bladder. The transobturator approach passes the tape through the obturator foramen, a natural opening in the pelvic bone on each side. This keeps the tape farther from the bladder but closer to the nerves and muscles of the inner thigh.

Meta-analyses have consistently found that the two approaches produce similar long-term cure rates. One systematic review found no significant difference in objective or subjective cure rates between TVT and TOT over the long term.⁶ Another meta-analysis found that the transobturator approach had shorter operating times and hospital stays, though the differences in blood loss and overall complication rates were not statistically significant.⁷

Where the two routes differ meaningfully is in the type of complications they produce. The retropubic approach carries a higher risk of bladder perforation during the procedure, while the transobturator approach is more likely to cause groin or thigh pain afterward. A systematic review comparing the two found that transobturator slings reduced the risk of bladder perforation substantially, while the retropubic approach was associated with lower rates of groin pain. The transobturator route also showed lower risk of long-term voiding dysfunction in one subgroup analysis.⁸ The choice between them often comes down to a patient’s anatomy, risk profile, and surgeon preference rather than a clear superiority of one route.

Single-Incision Mini-Slings

A newer generation of slings uses a shorter strip of mesh inserted through a single small vaginal incision, avoiding the deeper tissue tunnels of the retropubic and transobturator routes. These “mini-slings” appeal to both surgeons and patients because they use less mesh overall and may cause less postoperative pain in the groin and thigh.

A large randomized trial published in the New England Journal of Medicine found that mini-slings were not inferior to standard midurethral slings. At 15 months, about 79% of women in the mini-sling group reported success compared to about 76% with standard slings. At three years, success rates were roughly 72% and 67% respectively.⁹ A linked health technology assessment confirmed these findings and added an important detail: tape or mesh exposure was somewhat more common with the mini-sling, at about 3.3% over three years compared with roughly 2% for standard slings.¹⁰

A separate meta-analysis found the clinical effectiveness of mini-slings comparable to standard midurethral slings, with a shorter operating time and lower rates of pelvic and groin pain. The tradeoff was a higher incidence of pain during intercourse.¹¹ Mini-slings are gaining ground, but the evidence base is still younger than that for TVT and TOT, and not all surgeons have adopted them.

Autologous Slings Made from Your Own Tissue

Not all bladder slings use synthetic mesh. An older approach, called a pubovaginal sling, uses a strip of fascia harvested from the patient’s own body, usually from the abdominal wall (rectus fascia) or, less commonly, the outer thigh (fascia lata). Because the material comes from your own body, there is no foreign-body reaction and no risk of mesh erosion or extrusion.

The catch is that the surgery is more involved. You need a second incision to harvest the tissue, which increases operating time, hospital stay, and postoperative pain. A retrospective study comparing the two found that autologous slings had higher morbidity at about 13% compared to roughly 5% for synthetic slings, though success rates and quality-of-life outcomes were similar between the groups. The highest complete cure rate in that study, about 94%, was actually in the synthetic group.¹²

A larger analysis using a national surgical registry found that autologous fascia slings were associated with more than three times the odds of perioperative adverse events compared to synthetic mesh slings, even after adjusting for patient characteristics.¹³ A meta-analysis comparing midurethral tape to autologous fascial slings found that synthetic TVT had advantages in surgical duration and complication rates, though transobturator slings compared favorably to autologous slings in terms of operating time, hospital stay, and wound complications.¹⁴

Despite these drawbacks, autologous slings remain a valuable option for women who cannot or do not want to have synthetic mesh placed in their bodies. They are also sometimes preferred in patients who have already had a mesh-related complication or in specific clinical scenarios where the surgeon judges the added tissue harvest to be worthwhile.

Known Complications of Synthetic Slings

Even though midurethral slings are well-established with high success rates, they are not complication-free. Reported problems include bleeding, bladder or urethral injury during placement, mesh erosion into the urethra or bladder, vaginal extrusion of mesh, urinary tract infection, new or worsened urgency, pain, and bladder outlet obstruction.¹⁵ Most of these are uncommon, but they are not rare enough to ignore.

A Taiwanese cohort study tracking outcomes for five years found that surgical complications, defined as needing a second surgery or developing urinary retention, occurred in about 5% of patients. The transobturator-outside-in variant (TVT-O) and hormone replacement therapy use were both identified as risk factors for urinary retention specifically.¹⁶

Part of the complication story relates to what happens to polypropylene inside the body over time. Although polypropylene was long considered biologically inert, research has documented various forms of degradation after implantation, including oxidative breakdown, stress cracking, loss of structural integrity, and mesh shrinkage. These chemical changes can produce visible fiber damage and embrittlement of the material.¹⁷ The broader mesh literature has found that structural properties like pore size play a bigger role in how the body responds than the simple weight of the mesh. Larger pores allow better tissue growth and produce less inflammation and scarring.¹⁸

Long-Term Outcomes and Removal Rates

One of the most reassuring data points for women considering a midurethral sling is how infrequently the mesh needs to be taken out. A large study found that the rate of mesh sling removal was about 1.4% at one year, 2.7% at five years, and 3.3% at nine years. Reoperation for recurrent incontinence was somewhat more common, at about 3.5% by five years and 4.5% by nine years.¹⁹ Those numbers mean that the vast majority of women who get a midurethral sling will never need another surgery related to it.

A retrospective cohort study looking at outcomes about eight years after midurethral sling surgery found that about 24% of patients reported some urinary incontinence symptoms during follow-up. Of those, roughly half had stress incontinence and the other half had urgency incontinence, which is a different condition that slings are not designed to treat. Only about 3% received additional surgery, including a small number who had the sling removed or a second sling placed.²⁰

What Happens When a Sling Needs to Come Out

If a sling causes persistent voiding problems, pain, or mesh erosion, partial or complete removal is an option. A study of women who underwent sling removal for chronic voiding dysfunction found significant improvement in symptoms afterward, with only one patient out of the group requiring further intervention for ongoing difficulties.²¹

For mesh that has eroded into the urethra or bladder, the surgical approach to removal matters. A systematic review found that when mesh had eroded into the urethra, a transvaginal approach showed a trend toward better symptom resolution and fewer additional procedures. For mesh in the bladder, abdominal and cystoscopic approaches resolved symptoms at similar rates, but the abdominal approach required fewer follow-up interventions.²² These are uncommon situations, but knowing that effective treatment exists for mesh complications is part of informed decision-making.

How Perception Has Shaped Access

The regulatory and legal landscape around vaginal mesh has had consequences beyond the products that were actually problematic. After the FDA’s 2011 safety communication and the subsequent wave of lawsuits, the litigation was overwhelmingly directed at suburethral sling tapes rather than at transvaginal mesh for prolapse, even though slings remained the established gold standard for stress incontinence. Manufacturers were sued in over 99% of cases, while treating physicians were named in fewer than 1%.²³

This mismatch between where the clinical evidence pointed and where the legal and media attention landed has shaped patient attitudes. A survey of women referred to a urogynecology clinic found that concerns about mesh surgery, having heard about mesh from friends or family, and awareness of class-action lawsuits were all significantly associated with being unwilling to consider mesh-based surgery in the future.²⁴ For some women, that means forgoing a well-studied, effective incontinence procedure based on fears that apply more accurately to a different operation.

Nonsurgical and Less Invasive Alternatives

For women who want to avoid surgery entirely, pelvic floor muscle training remains a first-line treatment for stress urinary incontinence. It works by strengthening the muscles that support the urethra and bladder neck, and while it requires consistent effort over weeks to months, it carries no surgical risk. Urethral bulking agents are another less invasive option: a gel-like material is injected around the urethra to add volume and improve closure.²⁵ Bulking agents can be done in an office setting and are especially useful for patients whose other health conditions make surgery risky. The tradeoff is that bulking agents tend to be less durable than slings and may need to be repeated.

The decision tree for stress incontinence treatment typically starts with pelvic floor exercises, moves to bulking agents or pessaries if those are insufficient, and arrives at a sling procedure when conservative measures have not provided enough relief. Within the sling category, the choice between synthetic mesh (retropubic, transobturator, or mini-sling) and autologous fascia depends on the patient’s preferences, anatomy, prior surgical history, and how they weigh the different risk profiles. There is no single right answer, but understanding that “sling” and “mesh” describe different aspects of the same treatment, and that neither term is synonymous with the banned transvaginal prolapse mesh, is the foundation for a clearer conversation with your surgeon.